ETV6 (ets translocation variant gene 6) TEL (translocation ets leukemia), encoding a transcriptional repressor, is involved in various translocations associated with human malignancies. Strikingly, the nonrearranged ETV6 allele is often deleted or inactivated in cells harboring these translocations. Although ETV6 translocations are infrequent in acute myeloid leukemia (AML), mutations or deregulated expression of ETV6 may contribute to leukemogenesis. To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. Furthermore, we studied protein expression in 77 patients using two ETV6-specific antibodies. Five somatic heterozygous mutations were detected, which affected either the homodimerization-or the DNA-binding domain of ETV6. The proteins translated from the cDNAs of these mutants were unable to repress transcription and showed dominant-negative effects. In addition, we demonstrate that one-third of AML patients have deficient ETV6 protein expression, which is not related to ETV6 mRNA expression levels. In conclusion, we demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought. Additional comprehensive studies are required to define the clinical consequence of ETV6 loss of function in AML.
Introduction
The ETV6 (ets translocation variant gene 6) gene also known as TEL (translocation ets leukemia) is located on the short arm of chromosome 12 and is involved in various translocations associated with human malignancies (Wlodarska et al., 1996; Odero et al., 2001) . ETV6 encodes a transcriptional repressor with two functional domains: a C-terminal DNA-binding domain (ETSdomain) (Poirel et al., 1997; Lopez et al., 1999 ) that recognizes ETS binding sites (EBS) in promoter regions of target genes (Kwiatkowski et al., 1998; Fenrick et al., 2000) and an N-terminal pointed (PNT) homodimerization domain (Golub et al., 1994) . Dimerization of ETV6 through the PNT domain is indispensable for transcription repression (Lopez et al., 1999) .
The repression of target genes by ETV6 appears to be important in the regulation of cell growth and differentiation, since expression of ETV6 in Ras-transformed NIH 3T3 cells inhibits cell growth through repression of target genes such as stromelysin-1 (Fenrick et al., 2000) . Moreover, ETV6 has been shown to stimulate erythroid differentiation of the murine erythroid leukemia cell line (Waga et al., 2003) . ETV6 knockout mice are embryonic lethal at days 10.5-11.5 and exhibit defects in yolk sac angiogenesis and intraembryonic apoptosis of mesenchymal and neural cells. Although ETV6 deficiency does not affect hematopoiesis at the yolk sac stage (Wang et al., 1997) , it is indispensable for the development of all lineages in adult bone marrow. Chimeric mice with ETV6 knockout embryonic stem cells present defective hematopoiesis within the first week after birth (Wang et al., 1998) .
The fusion partners of ETV6 in translocations are heterogeneous and encompass kinases as well as transcription factors. Furthermore, the contribution of ETV6 to the oncogenic fusion proteins is variable. As a consequence of translocation t(3;12)(q26;p13), the ETV6 promoter is situated in the vicinity of the EVI1 gene, which in certain cases results in overexpression of an otherwise normal EVI-1 protein (Iwase et al., 1998) . In several other translocations, the N-terminal part of ETV6, which contains a strong dimerization domain, is fused to kinases or transcription factors, resulting in constitutive activation of the fusion partners, for example, in ETV6-PDGFRb (Carroll et al., 1996; Jousset et al., 1997) , ETV6-ABL and ETV6-AML1 (Hiebert et al., 1996) . In other cases, ETV6 provides the ETS DNA binding site to a fusion protein resulting in a transcription factor with altered characteristics, for example, in ETV6-MN or BTL-ETV6 (Cools et al., 1999) . ETV6-AML1, which is generated as a result of translocation t(12;21)(p13;q22), is the most common genetic lesion in pediatric acute lymphoblastic leukemia (ALL). This translocation is detected in up to 25-30% of the patients and often associates with a fully or partially deleted nonrearranged ETV6 allele (Romana et al., 1995; Shurtleff et al., 1995; Romana et al., 1996) . Deletion of the wild-type (wt) allele in these cases results in the loss of ETV6 expression, which might contribute to the pathogenesis of the disease. A few studies have demonstrated that deletion of the wt ETV6 allele in cases with t(12;21)(p13;q22) is not the only mechanism that leads to the loss of functional ETV6 (Poirel et al., 1998; Patel et al., 2003) . Loss of wt ETV6 expression was also found as the result of small structural abnormalities or epigenetic modification (Patel et al., 2003) . ETV6 abnormalities in ALL are not restricted to translocations or deletions. Approximately 23% of ALL patients that do not carry a t(12;21) show an abnormal expression pattern of ETV6 isoforms (Agape et al., 1997) . Although ETV6 translocations are infrequent in AML (Hernandez et al., 2000) , an abnormal expression pattern or mutations in ETV6 might contribute to the pathogenesis of the disease. Kibel et al. (2002 Kibel et al. ( , 1999 have demonstrated ETV6 mutations in two out of 19 patients with prostate carcinoma, in three of 25 xenografts, that is, human tumors transplanted into athymic mice and in various cell lines. The mutations in ETV6 often associated with loss of heterozygosity, which fits with the classic two-hit gene inactivation hypothesis (Kibel et al., 2002) . To investigate the involvement of ETV6 in AML, we analysed 300 newly diagnosed patients for mutations in the coding region of the gene. We identified five cases of AML with nonsense/frameshift mutations or in-frame insertions in ETV6 and investigated the effects of these mutants in vitro. Furthermore, we studied protein expression in 77 newly diagnosed AML patients using two ETV6-specific antibodies. We demonstrate that despite of considerable ETV6 mRNA expression, the protein is frequently absent in AML blasts.
Results

Somatic heterozygous ETV6 mutations in de novo AML
Nucleotide sequence analysis was carried out on ETV6 cDNA generated from mRNA samples, prepared from leukemic blast cells of 300 AML patients. The analysis revealed seven distinct and novel heterozygous mutations in the coding region of ETV6 (Table 1) . In addition to these mutations, we observed two previously described polymorphisms at nucleotide 532 (G-A, ThrThr) and 876 (T-C, Leu-Pro) in 17 and 5% of the patients, respectively. Furthermore, we detected a rare polymorphism at nucleotide 654 (G-A, Arg-Gln) in four patients. This polymorphism has been described previously in a CWR31 xenograft (Kibel et al., 2002) .
From the seven mutations identified, two were silent point mutations at nucleotide 1159 (C-T) and 1349 (C-A), while the other mutations (#2210, 2290, 2236, 2649 and 3102) affected the predicted amino-acid sequence and, consequently, the structure of the protein ( Table 1 ). The presence of these mutations was confirmed by nucleotidesequencing analysis on genomic DNA isolated from leukemic blasts of the same patients. The wt nonmutated ETV6 was observed in equal levels as the mutated forms. Nucleotide-sequence analysis on genomic DNA extracted from nonhematopoietic tissues (skin or intestine) of patient #2210, 2290 and 2236 revealed the absence of mutations, indicating that the ETV6 mutations were somatically related to leukemia. Interestingly, four out of the five mutations that affected ETV6 protein structure occurred in the well-characterized functional domains of ETV6, that is, two (#2210 and 2290) in the pointed (PNT) domain and two (#2649 and 3102) in the DNA-binding ETS domain (Figure 1 ). Mutation #2236 is situated three amino-acid downstream of the PNT domain. The mutations in cases #2210, 2290, 2236 and 3102 resulted in an early stop whereas the in-frame mutation (GGG) in-patient #2649, introduced an extra glycine between amino acid 344 and 345. The clinical and cytogenetic characteristics of the patients are summarized in Table 1 . The functional mutations in ETV6 associated with FAB subtype M1 and M2.
Abnormal ETV6 proteins translated from the cDNAs of the mutants
We next studied the effects of the structural mutations on ETV6 protein expression using ETV6 cDNA. Mutant ETV6 cDNAs obtained from four patients (#2290, 2236, 3102 and 2649) were cloned into pCMV and transfected into phoenix cells. Subsequently, the expression of ETV6 constructs was studied by Western blot analysis using specific anti-ETV6 antibodies. As expected, the wt construct produced two isoforms (50 and 57 kDa), starting from the first two in frame ATGs (codons 1 and 43) (Poirel et al., 1997) . These isoforms were detectable by the antibody directed to the C-terminal part of ETV6 (Figures 1 and 2 ). The antibody directed to the first 54 amino-acids of ETV6 (the N-terminal antibody) was only able to recognize the 57 kDa wt protein (Figures 1 and 2 ).
N-terminal mutants
Western blot analysis of cells transfected with ETV6 mutant #2290 showed no ETV6 bands when stained with N-terminal ETV6 antibody ( Figure 2a ). However, staining with C-terminal ETV6 antibody revealed three short fragments (44, 28 and 23 kDa) ( Figure 2b ). These bands were not observed when wt ETV6 was introduced into these cells ( Figure 2b ). To investigate whether these short fragments are generated by translation initiation from alternative ATGs, we mutated putative ATG-start codons in cDNA #2290 into ACG. Mutation of the ATGs representing methionine M89, M208 or M240, resulted in the disappearance of the 44, 28 and 23 kDa proteins, respectively ( Figure 2c ). However, mutating the other ATGs (methionine M315 or M319) had no effects on the distinct protein bands (data not shown). Using the N-terminal ETV6 antibody, we demonstrated the production of an expected short 20 kDa ETV6 protein in phoenix cells transfected with cDNA #2236 (Figure 2a ). The expression of the short C-terminal ETV6 fragments was significantly reduced as compared to the mutant #2290 ( Figure 2b ).
C-terminal mutants
The frame-shift mutation in #3102 presented an expected 48 kDa band, which could be detected by both C-and N-terminal ETV6 antibodies. However, the presence of an 18 kDa fragment in #3102, detected by N-terminal antibody, was unexpected ( Figure 2a ). As expected, the in-frame mutation in patient #2649 did not visibly alter the ETV6 protein size in transfected phoenix cells.
Mutant ETV6 in AML samples
AML blasts from three patients with ETV6 mutations were available for Western blot analysis: Mutations in the PNT domain give rise to the production of several short C-terminal fragments (44, 28, 23 kDa), which are generated by translation initiation from methionine M89, M208 and M240. (c) The Cterminal ETV6 mutant #3102 has a frame-shift mutation, whereas the mutation in #2649 is in-frame. In both cases, the ETS DNAbinding domain is affected. (d) The N and C constructs used for luciferase assay; N expresses the N-terminal half of ETV6, while C expresses the two C-terminal fragments of 28 and 23 kDa.
Figure 2
Western blot analysis on the lysates of phoenix cells transfected with different ETV6 constructs. The proteins generated by the wt construct (WT) or the mutants are stained with (a) the N-terminal ETV6 antibody (Nab, Figure 1a ) and (b) the C-terminal ETV6 antibody (Cab, Figure 1a ). (c) Using the C-terminal ETV6 antibody, we demonstrate that the 44, 28 and 23 kDa fragments are generated by methionine M89, M208 and M240, respectively. In each construct, an ATG is mutated into ACG (DM89, DM208 and DM240).
ETV6 mutations and deficit ETV6 expression in AML S Barjesteh van Waalwijk van Doorn-Khosrovani et al N-terminal mutants Western blot analysis on the protein lysate, obtained from AML blasts of patient #2290, revealed complete absence of the 57 and 50 kDa ETV6 proteins, using N-and C-terminal ETV6 antibodies ( Figure 3a) . The same was observed in cells from patient #3, which did not harbor mutations in ETV6.
Using the C-terminal ETV6 antibody, multiple smaller fragments could be identified. These smaller bands were also observed in CD34 þ bone marrow cells and in the other AML blasts samples, irrespective of ETV6 mutation (Figure 3a) . Western blot analysis comparing patient samples with phoenix cells transfected with ETV6 construct #2290 revealed that the bands correspond to the sizes of C-terminal ETV6 isoforms (44, 28 and 23 kDa) (Figure 3b ). Taken together, these data suggest that ETV6 has normally several short C-terminal isoforms, which lack the N-terminal homodimerization domain. Certain AML cases, such as patient #3 and #2290, express only these short isoforms of ETV6. Western blot analysis using N-terminal ETV6 antibodies failed to show the short N-terminal protein 
in mutant #2236 (data not shown). The normal sized isoforms (57 and 55 kDa) produced by the nonmutated allele and the short C-terminal ETV6 fragments could be detected by C-terminal ETV6 antibody (Figure 3a) .
C-terminal mutant Neither the N-nor C-terminal specific antibodies were capable in detecting the expected 48 kDa ETV6 protein in case #3102. The normal sized isoforms (57 and 55 kDa) produced by the nonmutated allele and the short C-terminal ETV6 fragments could be detected in this case (Figure 3a) .
Deficient ETV6 protein expression in one-third of the patients with AML
Western blot analysis on samples from three AML patients with intact ETV6 alleles revealed the lack of ETV6 protein expression in one case (patient #3, Figure 3a) . To investigate the relevance of this finding and to determine the frequency of ETV6 protein loss, we studied ETV6 protein expression in 77 AML patients. The presence of ETV6 protein was studied by Western blot analysis using the C-terminal ETV6 antibody. Immunostaining with ERK1 antibody demonstrated equal loading of the samples on the Western blot. Surprisingly, 24 cases lacked the 57 and 50 kDa ETV6 proteins (Figure 3c ). However, all the patients showed expression of shorter bands that corresponded to the sizes of the C-terminal short isoforms of ETV6 detected in patient #2290 (44, 28 and 23 kDa). The clinical characteristics of the 77 AML cases studied by Western blot analysis are listed in Table 2 . The distribution of ETV6-negative cases varies between distinct karyotypic risk groups. Remarkably, all the unfavorable-risk patients studied expressed ETV6 protein, whereas the majority of favorable-risk patients showed no expression.
To investigate whether the absence of ETV6 protein was the consequence of altered transcription, we investigated the levels of ETV6 mRNA in these AML cases. Previously, we had determined gene expression profiles of 285 AML cases (Valk et al., 2004) , which included the 77 cases that were investigated in the present study. Analysis of mRNA hybridization to the ETV6-probe set on the gene chip (Affymetrix U133A GeneChip) revealed various levels of ETV6 mRNA expression among these cases. However, we did not observe any correlation between ETV6 mRNA transcript levels and the loss of ETV6 protein (Figure 3d) . To validate the gene-chip data, we carried out quantitative real-time PCR analysis on ETV6 transcripts using cDNA of three AML cases with ETV6 protein and three cases in whom the ETV6 protein was absent. In all these cases, comparable levels of ETV6 mRNA were detected irrespective of the absence or presence of ETV6 protein (data not shown).
ETV6 mutants and the short C-terminal isoforms of ETV6 lack transcription repression properties
Using a luciferase reporter assay applying the pGL2-754TR reporter construct, which contains EBS, we determined the transactivation repressing properties of distinct ETV6 mutants including those that generate short C-terminal ETV6 isoforms (#2290 and C (see Figure 1b and d) ). Figure 4a shows significant repression of luciferase activity by the wt ETV6. The mutants expressing C-terminal ETV6 isoforms (#2290 and C) as well as other mutants of ETV6 (#2236, 3102 and 2649) were unable to repress luciferase activity. Remarkably, the luciferase activity following transfection of the mutants was even higher than the basal levels observed with the empty vector control. This effect might be caused by a dominant-negative effect of the mutants on a possible low endogenous repression activity in phoenix cells.
ETV6 mutants act as dominant negatives in a luciferase repression assay
In order to investigate whether mutant ETV6 constructs harbor dominant-negative activity, wt ETV6 (15 ng) was cotransfected with 100 ng of the ETV6 mutants (Figure 4b ). N-terminal mutant Both N-terminal ETV6 mutants (#2290 and 2236) abolished the transactivation repression property of the wt ETV6. However, the inhibition by #2236 was much stronger than #2290 that only expresses short C-terminal isoforms. Similar to #2290, the C-terminal construct (C), which expresses two Cterminal ETV6 isoforms (28 and 23 kDa) showed weak dominant-negative effect on the wt. 
C-terminal mutant
The two C-terminal mutants (#3102 and 2649) had dominant-negative effects and completely abolished the ETV6-induced repression (Figure 4b ). The dominant-negative effect of truncated ETV6 proteins seems to be strong in the presence of an intact homodimerization domain. Accordingly, the constructs encoding the N-terminal half of ETV6 (N) had a negative effect on the wt ETV6.
Discussion
In this study, we report the occurrence of somatic heterozygous mutations of the ETV6 gene in de novo AML patients. Furthermore, we demonstrate deficient ETV6 protein expression in one-third of AML patients. Several studies have demonstrated the involvement of ETV6 in distinct chromosomal translocations associated with hematological malignancies Carroll et al., 1996; Golub et al., 1994 Golub et al., , 1995 Golub et al., , 1996 Hiebert et al., 1996; Jousset et al., 1997; Cools et al., 1999) . However, to our knowledge, aberrant ETV6 expression in human AML has not been reported before. The functional ETV6 mutations identified in this study affected either the PNT domain in the Nterminus or the C-terminal DNA-binding ETS domain.
The three mutations in the N-terminus resulted in premature termination of translation by either single point mutation or out-of-frame insertion/deletion. Although translation of the 57 and 50 kDa isoforms was truncated, peptides of 44, 28 and 23 kDa were translated starting from M89, M208 or M240, respectively. The C-terminal ETV6 mutations were either inframe or resulted in truncation of the ETS domain by out-of-frame mutation. In concordance with earlier studies (Waga et al., 2003; Wood et al., 2003) , the truncated ETV6 proteins were impaired in repressing transcription in a ETV6-specific luciferase assay. Moreover, coexpression of the mutants with an intact homodimerization domain (#2236, 3102, 2649 and N) completely abolished the transcription repression by wt ETV6. Although this is in accordance with the fact that dimerization of ETV6 through the PNT domain is indispensable for EBS-driven transcriptional repression (Lopez et al., 1999) , one should keep in mind that the dominant-negative effects were observed with seven times the amounts of the dominant-negative ETV6 as compared to wt, a situation which is not found in AML. The fact that despite the equal mutant/wt transcript levels (data not shown), no abnormal protein could be detected is intriguing. Nonsense or frame-shift mutations that generate premature termination codons have been observed in many forms of cancer (Brimmell et al., 1998; Liu et al., 2000; Goseki-Sone et al., 2001; Perrin-Vidoz et al., 2002; Lamba et al., 2003; Plaschke et al., 2004) . However, the predominant consequence of such mutations is not always the synthesis of truncated proteins (Frischmeyer and Dietz, 1999) . Western blot analysis on the protein extracts obtained from AML blasts of two mutants (#2236 and 3102) failed to show the expression of truncated ETV6 proteins. Generally, the absence of abnormal protein is justified by the possible degradation of mutant transcripts through a nonsense-mediated mRNA decay pathway (Losson and Lacroute, 1979; Frischmeyer and Dietz, 1999; Schell et al., 2002) . Nucleotide sequence analysis on patient #2236 demonstrated that the mutant transcript level was decreased to only one-third of the wt level (data not shown). All the other patients with mutations presented no evidence of nonsense-mediated decay, as the ETV6 mutant transcript levels in these cases were as abundant as the wt ETV6. The fact that truncated ETV6 proteins are undetectable in the bulk of the AML cells does not exclude their potential involvement in AML development. Only a minority of the AML cells, that is, the AML colony-forming cells (AML-CFU), proliferate and give rise to undifferentiated AML progeny (Lowenberg and Bauman, 1985) . It is possible that the expression of truncated ETV6 proteins is restricted to this proliferating subset of AML cells. 
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Western blot analysis using cell lysates from AML blasts and normal CD34 þ cells suggested the expression of short C-terminal ETV6 peptides. These Cterminal ETV6 isoforms, generated by downstream initiation codons, may regulate the repressing properties of wt ETV6. Accordingly, the abnormal ratio of different ETV6 isoforms may relate to leukemia. In this study, we demonstrated that the wt ETV6 isoforms (57 and 50 kDa) are absent in one-third of AML cases. The absence of ETV6 expression is also observed in ALL cases with t(12;21) (Poirel et al., 1998; Patel et al., 2003) . Loss of ETV6 expression in these cases seems to be a critical secondary event for leukemogenesis, as expression of the ETV6/AML1 fusion protein alone is not sufficient for the induction of malignant hematological disorder in transgenic mice (Andreasson et al., 2001) . In ALL cases without t(12;21), the wt ETV6 protein is present; however, the expression level and the ratio of the two 57 and 50 kDa ETV6 isoforms can be altered (Agape et al., 1997) . It is presently unknown why ETV6 protein is absent in some AML cases. The absence of protein in the presence of significant levels of mRNA suggests that ETV6 is post-transcriptionally regulated. Joosten et al. (2004) have demonstrated that Nm23M2 mRNA can be largely nonpolysome bound and therefore not translated. However, upon stimulation of growth factors such as Epo, SCF, IL3 or G-CSF, Nm23M2 mRNA relocates to the polysomes. It would be interesting to investigate the ratio of subpolysomalversus polysome-bound ETV6 in distinct AML samples. Furthermore, nucleotide-sequencing analysis of the 5 0 -and 3 0 -untranslated regions of ETV6 mRNA might reveal mutations or polymorphisms, which could explain the ETV6 protein loss. Other explanations for the ETV6 protein loss are alterations in the pathways that regulate translation or accelerated ETV6 protein degradation.
The data presented here demonstrate that ETV6 abnormalities are not restricted to translocations and occur more frequently in AML than previously thought, that is, either by somatic mutations or by the absence of wt ETV6 protein through a currently unknown mechanism. A comprehensive study in a large series of AML patients is needed to define the clinical consequence of ETV6 loss of function.
Materials and methods
Patient samples
Bone marrow samples of a total of 300 de novo AML patients at diagnosis were obtained after informed consent. Bone marrow blast cells were purified as described and further processed for DNA, RNA or protein isolation. DNA and mRNA isolation as well as cDNA synthesis were performed according to standard protocols (Barjesteh van Waalwijk van . DNA samples isolated from nonhematopoietic tissues (skin or intestinal) of three patients with ETV6 mutations were provided by the Department of Pathology at Erasmus MC Rotterdam, The Netherlands.
Polymerase chain reaction (PCR) and direct sequencing
The entire coding region of ETV6 was amplified using 20 pmol foward primer (FW: 5 0 -ttctgggttggggagag-3 0 ) and 20 pmol reverse primer (REV: 5 0 -cgctgaggtggactgttg-3 0 ). In brief, the reaction was performed in 50 ml, using 1.7 U Expand HighFidelity enzyme, 5 ml PCR buffer, 2 mM MgCl 2 (Roche diagnostics GmbH, Mannheim, Germany), 1 mM dNTPs (Amersham Pharmacia Biotech Inc., Roosendaal, The Netherlands) and cDNA. The thermal cycling conditions included 5 min at 951C followed by 30 cycles of 1 min at 951C, 1 min at 531C, 3 min at 721C and a final step of 10 min at 721C. PCR products were purified on Montage PCR 96 filter plates (Millipore Corporation) and sequenced in both directions using ABI Prism 3100 Genetic Analyser (PE Applied Biosystems) and 10 pmol primer (FW: FW mid, 5 0 -tcccaccattgaactgt-3 0 ; REV: REV mid, 5 0 -cggtgatttgtcgtgatag-3 0 ). Similar PCR and sequencing conditions were used to confirm the mutations on genomic DNA using specific primers for exon 3 (FW: 5 0 -ggctcttgagatgtggaga-3 0 ; REV: 5 0 -catcccttccttgtgatga-3 0 ) exon 4 (FW: 5 0 -caggtgcgctccaattgta-3 0 ; REV: 5 0 -acacgaagaa gaccagctta-3 0 ) and exons 6 and 7 (FW: 5 0 -tcttctggttagtgcctcaa-3 0 ; REV: 5 0 -caggtagagatcttaacagt-3 0 ).
Constructs
N-and C-terminal constructs of ETV6 were generated by PCR with primer combination FW-REVmid and Fwmid-REV, respectively. All PCR products were cloned into the TA vector (Promega) followed by subcloning into EcoRI sites of mammalian expression vector pCMV, which is derived from the pEGFP-C1 vector (Clonetech Lab, Palo Alto, CA, USA), from which the EGFP fragment was removed following Nhe1 and Xho1 digestion and subsequent religation. Single point mutations were generated in methionine residues 208, 240, 315 and 319 of the #2290 construct cloned into pCMV using QuikChange Site-Directed Mutagenesis kit (Stratagene, CA, USA). The oligonucleotide sequence of the sense and antisense primers are available upon request.
Immunoblotting
Phoenix cells were maintained in Dulbecco's modified medium (Life Technologies, Breda, The Netherlands) with 10% FCS. At 24 h prior transfection, cells were plated onto 10 cm dishes at a density of 2 Â 10 6 cells/10 ml culture medium. Cells were transfected with 20 mg of corresponding ETV6 construct. At 48 h post-transfection, cells were harvested and lysed on ice for 15 min in lysis buffer (Tris-HCl (pH 8.0), 20 mM, NaCl 137 mM, EDTA 10 mM, NaF 100 mM, NP-40 1% and glycerol 10%) supplemented with Complete protease inhibitor mix and Pefablock (Roche), and centrifuged at 41C for 10 min at 14 000 r.p.m.
ETV6 protein in AML patient samples was detected as follows: AML bone marrow samples were thawed and cultured for 1 h in RPMI (Invitrogen) þ 5% FCS to deplete monocytes. The nonadherent fraction was taken, washed once in cold PBS and lysed in cold lysis buffer as described above. The protein concentration was measured using the BCA Protein Assay Kit (Rockford, Pierce) according to the manufacturer's protocol. Protein extracts (35 mg total protein/lane) were fractionated on SDS-12% polyacrylamide gels and transferred to nitrocellulose membranes by electroblotting. The ETV6 protein was detected by rabbit polyclonal antibodies (1 : 1000) directed either to the first 54 amino acid or to the C-terminal half of ETV6 protein (serum #68 and 71, respectively, provided by J Ghysdael, Institut Curie, Orsay, France). Polyclonal swine anti-rabbit immunoglobulins/HRP (DakoCytomation, Glostrup, Denmark) was applied as secondary antibody.
Luciferase assays
Luciferase assays were performed as described previously (Hermans et al., 2003) . In short, 8 Â 10 4 phoenix cells were seeded in 24-well dishes and transfected after 24 h by calcium phosphate precipitation method with corresponding plasmids. A volume of 100 ml calcium phosphate precipitate was used for each well with in total 2 mg of plasmid DNA. Cells were transduced with 1 mg of luciferase construct pGL2-754TR (provided by SW Hiebert, Vanderbilt University School of Medicine, TN, USA) containing EBS sites. Variable amounts (15-100 ng) of ETV6-containing plasmids plus 0.2 mg of LacZ supplemented with empty pCMV were cotransfected with the pGL2-754TR construct. The luciferase assay was carried out 48 h post-transfection. Cells were lysed in 100 ml lysis buffer (25 mM Tris-phosphate (pH 7.8), 15% glycerol, 1% Triton X-100, 1 mM DTT, 8 mM MgCl 2 ) and 25 ml was assayed for luciferase activity using steady-Glo reagents (Promega, Madison, WI, USA). Luciferase activity level was corrected for transfection efficiency using b-galactosidase expression levels. In brief, 25 ml of cell lysates were transferred to 96-well flat bottom plates (Costar, Corning Inc., Corning, NY, USA) and 75 ml of b-galactosidase substrate buffer (0.56 mg/ml onitrophenyl b-D-galactopyranosidase (Sigma), 100 mM NaPO 4 buffer (pH 7.8), 10 mM KCl, 1 mM MgSO 4 , 2.7 mM DTT) was added and incubated for 10 min at 371C. Activity was measured in a microplate reader (Biorad 450, Veendaal, The Netherlands) at 450 nm. All experiments were carried out in triplicate.
